Lexeo Therapeutics, Inc. (LXEO)
| Market Cap | 272.38M -23.8% |
| Revenue (ttm) | n/a |
| Net Income | -87.27M |
| EPS | -1.15 |
| Shares Out | 82.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,195,142 |
| Open | 3.270 |
| Previous Close | 3.300 |
| Day's Range | 3.220 - 3.465 |
| 52-Week Range | 2.980 - 10.990 |
| Beta | 1.64 |
| Analysts | Strong Buy |
| Price Target | 20.30 (+511.45%) |
| Est. Earnings | Nov 4, 2026 |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $20.3, which is an increase of 511.45% from the latest price.
News
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control co...
Lexeo Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Lead FA cardiomyopathy program is in a pivotal trial with data expected in 2027, complemented by new brain-targeted assets from a recent acquisition. PKP2 arrhythmogenic cardiomyopathy program shows promising efficacy and safety, with key data and regulatory updates due late 2026. Cash reserves exceed $230 million, supporting operations into 2028.
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (...
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced th...
Lexeo Therapeutics Transcript: M&A announcement
The acquisition of Mantle Therapeutics and new research collaborations significantly expand the FA platform, adding CNS-targeted and diversified therapeutic modalities. The $21.3M deal aims for comprehensive disease coverage, with prioritization updates and IND submission planned for 2027.
Lexeo Therapeutics Press release: M&A announcement
Lexeo Therapeutics issued a press release on September 22, 2026, disclosing material business information to investors.
Lexeo Therapeutics Slides: M&A announcement
Lexeo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
Lexeo Therapeutics enter into agreement to acquire Mantle Therapeutics
Lexeo Therapeutics (LXEO) announced a series of strategic transactions to expand its presence in Friedreich ataxia, including the signing of a definitive agreement to acquire Mantle Therapeutics and t...
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following ...
Lexeo Therapeutics Transcript: 2026 Global Healthcare Conference
Lead programs in Friedreich's ataxia and PKP2 cardiomyopathy show strong clinical progress, with pivotal and phase I studies advancing and key data readouts expected in 2026–2027. Regulatory and commercial strategies are tailored for rare cardiac diseases, supported by a robust cash position and focused market access plans.
Lexeo Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The event highlighted progress in gene therapies for FA and PKP2-ACM, emphasizing robust clinical data, scalable manufacturing, and expanding education and commercial efforts. Key endpoints and trial designs were discussed, with data readouts and further commercialization steps planned for the coming year.
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...
Lexeo Therapeutics reports Q2 EPS (30c), consensus (28c)
“We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,” said R. Nolan Townsend, Chief...
Lexeo Therapeutics Slides: Corporate presentation
Lexeo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first ...
Lexeo Therapeutics Earnings release: Q2 2026
Lexeo Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Lexeo Therapeutics Quarterly report: Q2 2026
Lexeo Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Lexeo Therapeutics management to meet with Cantor
Meeting to be held in New York on August 13 hosted by Cantor.
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM
Lexeo Therapeutics Transcript: Fireside chat
The discussion highlighted robust progress in the phase III FACM program, with strong clinical data, regulatory alignment, and a well-powered pivotal study. Durable improvements in cardiac and neurologic endpoints were noted, and the company is well-funded to reach key milestones.
Lexeo Therapeutics Transcript: AGM 2026
The meeting addressed the election of directors and auditor ratification, with both proposals passing. No questions were submitted by stockholders, and final voting results will be filed on Form 8-K.
Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan
JPMorgan lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $9 from $12 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect…
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies
Lexeo Therapeutics Transcript: Investor update
A pivotal trial for LX2006 in Friedreich's ataxia is set to begin, targeting accelerated approval with a robust design and strong phase I/II data showing significant cardiac and neurologic benefits. Enrollment is progressing, with top-line results expected in 2027 and a BLA filing in 2028.
Lexeo Therapeutics Slides: Investor update
Lexeo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.